ARK Genomic Revolution ETF (ARKG)
Performance
The fund's own total return, a year on average over the longer periods; volatility is the yearly standard deviation of its returns.
Volatility 40.6% over one year, 42.1% over three; Sharpe ratio over three years 0.63.
Largest components
| TEMTempus AI, Inc. Class A Common Stock | 8.88% | Healthcare | |
| TWSTTwist Bioscience Corp | 8.50% | Healthcare | |
| TXG10X Genomics Inc | 8.38% | Healthcare | |
| CRSPCrispr Therapeutics AG | 5.48% | Healthcare | |
| ILMNIllumina Inc | 4.82% | Healthcare | |
| NTRANatera Inc | 4.82% | Healthcare | |
| GHGuardant Health Inc | 4.75% | Healthcare | |
| ABSIAbsci Corp | 4.42% | Healthcare | |
| LLYEli Lilly and Company | 4.00% | Healthcare | |
| CDNACareDx Inc | 3.94% | Healthcare |
Sectors
Regions
Asset classes
About the fund
- Issuer
- ARK ETF Trust
- Since
- 2014-10-31
- Listed on
- BATS
- ISIN
- US00214Q3020
- Turnover
- 29% a year
The fund is an actively-managed exchange-traded fund (ETF) that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution (Genomics Revolution Companies). It is non-diversified.
From the market data provider's fund data, read 2026-10-19. Returns are the fund's own; past returns say nothing certain about future ones. None of this is advice.